133 related articles for article (PubMed ID: 7727857)
41. Clinical cancer research 2001: new agents and therapies.
Verweij J; de Vries EG
Drug Resist Updat; 2001 Aug; 4(4):217-23. PubMed ID: 11991676
[No Abstract] [Full Text] [Related]
42. [Chemotherapy-induced alopecia].
Spaëth D; Rosso N; Clivot L
Rev Prat; 2006 Nov; 56(18):2020-4. PubMed ID: 17274505
[TBL] [Abstract][Full Text] [Related]
43. Analysis of an individual chemotherapy assay system.
DiPaolo JA
Natl Cancer Inst Monogr; 1971 Dec; 34():240-5. PubMed ID: 5140869
[No Abstract] [Full Text] [Related]
44. Trimetrexate: overall clinical results.
Bertino JR
Semin Oncol; 1988 Apr; 15(2 Suppl 2):50-1. PubMed ID: 2966986
[No Abstract] [Full Text] [Related]
45. Acquired resistance to tyrosine kinase inhibitors during cancer therapy.
Engelman JA; Settleman J
Curr Opin Genet Dev; 2008 Feb; 18(1):73-9. PubMed ID: 18325754
[TBL] [Abstract][Full Text] [Related]
46. Current clinical and research approaches to optimizing regional chemotherapy: novel strategies generated through a better understanding of drug pharmacokinetics, drug resistance, and the development of clinically relevant animal models.
Beasley GM; Kahn L; Tyler DS
Surg Oncol Clin N Am; 2008 Oct; 17(4):731-58, vii-viii. PubMed ID: 18722915
[TBL] [Abstract][Full Text] [Related]
47. Modeling oxaliplatin drug delivery to circadian rhythms in drug metabolism and host tolerance.
Clairambault J
Adv Drug Deliv Rev; 2007 Aug; 59(9-10):1054-68. PubMed ID: 17707544
[TBL] [Abstract][Full Text] [Related]
48. [Determination of oncokinetic sensitivity].
von Ardenne M; Rieger F
Arch Geschwulstforsch; 1973; 42(1):17-33. PubMed ID: 4763852
[No Abstract] [Full Text] [Related]
49. Resisting arrest.
Holmes P
Nurs Times; 1990 Feb 7-13; 86(6):20-1. PubMed ID: 2304861
[No Abstract] [Full Text] [Related]
50. [Mechanisms of tumoral resistance to antineoplastic agents].
Albiero AL; Pozzi DH
Rev Assoc Med Bras (1992); 1994; 40(2):125-8. PubMed ID: 7820150
[No Abstract] [Full Text] [Related]
51. [Individualized drug therapy of cancer based on an in vitro test].
Tveit KM
Tidsskr Nor Laegeforen; 1983 Jan; 103(2):113-6. PubMed ID: 6845299
[No Abstract] [Full Text] [Related]
52. Molecular and clinical advances in anticancer drug resistance.
Cancer Treat Res; 1991; 57():1-308. PubMed ID: 1686711
[No Abstract] [Full Text] [Related]
53. Drug resistance in cancer: an overview of the clinical aspects.
Periti P; Mini E
J Chemother; 1989 Feb; 1(1):5-9. PubMed ID: 2656931
[TBL] [Abstract][Full Text] [Related]
54. Chemotherapy: the next decade.
Bagshawe KD
Proc R Soc Med; 1974 Aug; 67(8):745-6. PubMed ID: 4278901
[No Abstract] [Full Text] [Related]
55. [Sensitivity and resistance in tumor therapy].
Seeber S
Verh Dtsch Ges Inn Med; 1980; 86():367-77. PubMed ID: 7223028
[No Abstract] [Full Text] [Related]
56. [Mechanism of drug resistance in cancer and circumvention of resistance].
Suzuki H
Tanpakushitsu Kakusan Koso; 1988 Apr; 33(4):400-6. PubMed ID: 3041461
[No Abstract] [Full Text] [Related]
57. Cytokinetic aspects of clinical drug resistance.
Bender RA; Dedrick RL
Cancer Chemother Rep; 1975; 59(4):805-9. PubMed ID: 1175170
[No Abstract] [Full Text] [Related]
58. [Tests for first choice chemotherapy].
Sulkes A; Catane R; Fuchs Z
Harefuah; 1981 Mar; 100(5):249-50. PubMed ID: 7286827
[No Abstract] [Full Text] [Related]
59. Drug resistance in oncology: from concepts to applications.
Cazin JL; Gosselin P; Cappelaere P; Robert J; Demaille A
J Cancer Res Clin Oncol; 1992; 119(2):76-86. PubMed ID: 1429830
[TBL] [Abstract][Full Text] [Related]
60. Mathematical models of drug resistance and chemotherapy effects.
Goldie JH
Cancer Treat Res; 1989; 48():13-26. PubMed ID: 2577135
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
